Tamás Treuer

Eli Lilly (United States) — United States

Medicine · Health Sciences

24h-index2.1kcitations124works0.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Schizophrenia research and treatment(53), Bipolar Disorder and Treatment(34), Attention Deficit Hyperactivity Disorder(16), Rheumatoid Arthritis Research and Therapies(12), Treatment of Major Depression(11)

Publications124 total

Az igazságos rend ára
Humán Innovációs Szemle·2025Open Access
Dose Escalation Patterns and Associated Costs of Advanced Therapies for Ulcerative Colitis in France and the United Kingdom: A Retrospective Database Analysis
ClinicoEconomics and Outcomes Research·2025· 1 citedOpen Access
Baricitinib as monotherapy for treatment of rheumatoid arthritis: analysis of real-world data
Current Medical Research and Opinion·2024· 2 citedOpen Access
A nőgyűlölet eredete a patriarchális társadalomban
Humán Innovációs Szemle·2024Open Access
P94 Real-world evidence study of dose escalation and associated costs of advanced therapies for ulcerative colitis in France and United Kingdom
Poster presentations·2024
POS0158-PARE FATIGUE, JOINT AND MUSCLE PAIN ARE LEADING BOTHERSOME SYMPTOMS FOR PATIENTS WITH SLE IRRESPECTIVE OF ETHNICITY
Annals of the Rheumatic Diseases·2024
P912 A Real-World Evidence Study of Dose Escalation and associated costs of advanced therapies for Ulcerative Colitis in France and United Kingdom
Journal of Crohn s and Colitis·2024Open Access
Étude observationnelle prospective de 24 mois de la persistance du traitement chez des patients atteints de rhumatisme psoriasique (PRO-SPIRIT) – conception de l’étude et caractéristiques des patients à l’inclusion (échantillon complet)
Revue du Rhumatisme·2023
Real-world utilisation and switching between Janus kinase inhibitors in Australian patients with rheumatoid arthritis in the OPAL dataset
Clinical and Experimental Rheumatology·2023· 3 citedOpen Access
Systematic Literature Review of Real-World Evidence on Baricitinib for the Treatment of Rheumatoid Arthritis
Rheumatology and Therapy·2023· 18 citedOpen Access
Comparative Effectiveness of <scp>First‐Line</scp> Baricitinib in Patients With Rheumatoid Arthritis in the Australian <scp>OPAL</scp> Data Set
ACR Open Rheumatology·2023· 3 citedOpen Access
AB0456 BARICITINIB AS MONOTHERAPY FOR TREATMENT OF RHEUMATOID ARTHRITIS: SUMMARY OF DATA FROM FIVE REAL-WORLD DATA SOURCES
Annals of the Rheumatic Diseases·2023Open Access
AB1115 STUDY DESIGN AND FULL BASELINE SAMPLE CHARACTERISTICS OF PATIENTS FROM THE 24-MONTH MULTINATIONAL PROSPECTIVE PSORIATIC ARTHRITIS OBSERVATIONAL STUDY OF PERSISTENCE OF TREATMENT (PRO-SPIRIT)
Annals of the Rheumatic Diseases·2023· 2 citedOpen Access
P131 Time to Discontinuation and Effectiveness with Baricitinib in Rheumatoid Arthritis: 12-Month European Data from a Multinational, Prospective, Observational Study
Lara D. Veeken·2023· 1 citedOpen Access
P184 A 24-month prospective psoriatic arthritis observational study of persistence of treatment - interim analysis of baseline characteristics
Lara D. Veeken·2023Open Access
Real-world evidence for ixekizumab in the treatment of psoriasis and psoriatic arthritis: literature review 2016–2021
Journal of Dermatological Treatment·2023· 23 citedOpen Access
RWD69 Healthcare Resource Use by European Patients Enrolled in RA-BE-REAL: 12 Month Data From a Multinational, Prospective, Observational Study of Patients With Rheumatoid Arthritis
Value in Health·2022Open Access
Étude internationale, observationnelle et prospective chez des patients atteints de PR recevant du baricitinib, des tsDMARDs ou bDMARDs : délai avant arrêt du traitement, données d’efficacité, et PRO à 12 mois issus de la cohorte européenne
Revue du Rhumatisme·2022
Time to Discontinuation and Effectiveness with Baricitinib in Rheumatoid Arthritis: 12-Month European Data from a Multinational, Prospective, Observational Study
SPIRE - Sciences Po Institutional REpository·2022
Patient Characteristics, Treatment Patterns, Healthcare Resource Utilization, and Costs of Targeted Therapy-Eligible Atopic Dermatitis Patients in Taiwan—A Real-World Study
Dermatology and Therapy·2022· 2 citedOpen Access
page 1 of 7Next →

Frequent Co-authors

William Montgomery(10), Diego Novick(7), Kaname Ueda(6), Josep María Haro(6), Jamie Karagianis(6), Yulia Dyachkova(5), Ján Pečeňák(5), Martín Dossenbach(4), Héctor Dueñas(4), Mika Komori(3), Martin Anders(3), Wenyu Ye(3), Yongin Kim(3), Sarah Cotton(3), James Jackson(3), Richard Walton(3), A. Lowry(3), Vicki Poole Hoffmann(3), István Bitter(3), Ferenc Martényi(3)